The demands to reduce R&D costs in of new drugs and to improve the high attrition rate of drug candidates in development have shifted to early discovery phase the profiling activities to assess absorption,distribution metabolism,elimination and toxicity (ADMET) properties,along with the efficacy of drug candidates.Multiple predictive filters of ADMET properties (such as in silico,high-throughput in vitro and tailored mechanistic assays) are established in the various cascades of drug discovery and development process to flag and address the potential ADME and liability issues of new chemical entities (NCEs).An organization needs to establish a powerful landscape will lead to the most efficient and reliable prediction of in vivo ADMET matters in a timely and cost effective fashion.It is critical that,despite limited resource,increase in capacity should not be capitalized at the expense of deteriorated predictive power of the in vitro assays in early discovery.Meanwhile,collective utilization of those predictive tools will improve the productivity of drug discovery and development by prioritizing the drug-like NCEs,allowing candidates with poor drugability to be killed early and cheap.In this presentation,case studies will also be presented to demonstrate the impacts of those early in vitro predictive tools on the success of drug discovery projects.